Prognostic and predictive biomarkers of endocrine responsiveness for estrogen receptor positive breast cancer

Cynthia X. Ma, Ron Bose, Matthew J. Ellis

Research output: Chapter in Book/Report/Conference proceedingChapter

19 Scopus citations

Abstract

The estrogen-dependent nature of breast cancer is the fundamental basis for endocrine therapy. The presence of estrogen receptor (ER), the therapeutic target of endocrine therapy, is a prerequisite for this therapeutic approach. However, estrogen-independent growth often exists de novo at diagnosis or develops during the course of endocrine therapy. Therefore ER alone is insufficient in predicting endocrine therapy efficacy. Several RNA-based multigene assays are now available in clinical practice to assess distant recurrence risk, with majority of these assays evaluated in patients treated with 5 years of adjuvant endocrine therapy. While MammaPrint and Oncotype Dx are most predictive of recurrence risk within the first 5 years of diagnosis, Prosigna, Breast Cancer Index (BCI), and EndoPredict Clin have also demonstrated utility in predicting late recurrence. In addition, PAM50, or Prosigna, provides further biological insights by classifying breast cancers into intrinsic molecular subtypes. Additional strategies are under investigation in prospective clinical trials to differentiate endocrine sensitive and resistant tumors and include on-treatment Ki-67 and Preoperative Endocrine Prognostic Index (PEPI) score in the setting of neoadjuvant endocrine therapy. These biomarkers have become important tools in clinical practice for the identification of low risk patients for whom chemotherapy could be avoided. However, there is much work ahead toward the development of a molecular classification that informs the biology and novel therapeutic targets in high-risk disease as chemotherapy has only modest benefit in this population. The recognition of somatic mutations and their relationship to endocrine therapy responsiveness opens important opportunities toward this goal.

Original languageEnglish
Title of host publicationAdvances in Experimental Medicine and Biology
PublisherSpringer New York LLC
Pages125-154
Number of pages30
DOIs
StatePublished - Jan 1 2016

Publication series

NameAdvances in Experimental Medicine and Biology
Volume882
ISSN (Print)0065-2598
ISSN (Electronic)2214-8019

Keywords

  • BCI
  • EndoPredict
  • Endocrine therapy
  • Estrogen receptor positive breast cancer
  • MammaPrint
  • Multigene assay
  • Oncotype Dx
  • Prognostic markers
  • Prosigna
  • Risk of recurrence

Fingerprint Dive into the research topics of 'Prognostic and predictive biomarkers of endocrine responsiveness for estrogen receptor positive breast cancer'. Together they form a unique fingerprint.

  • Cite this

    Ma, C. X., Bose, R., & Ellis, M. J. (2016). Prognostic and predictive biomarkers of endocrine responsiveness for estrogen receptor positive breast cancer. In Advances in Experimental Medicine and Biology (pp. 125-154). (Advances in Experimental Medicine and Biology; Vol. 882). Springer New York LLC. https://doi.org/10.1007/978-3-319-22909-6_5